A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML

The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML).

Study Overview

• Status: Terminated
• Conditions: Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia
• Intervention / Treatment: Drug: Lanraplenib; Drug: Gilteritinib

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Spain
  • Barcelona, Spain, 08035
    • Hospital Universitari Vall d'Hebron
  • Barcelona, Spain, 08908
    • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
  • Barcelona, Spain, 170
    • Hospital Clinic De Barcelona
  • Cáceres, Spain, 10001
    • Hospital San Pedro de Alcantara
  • Madrid, Spain, 28040
    • Hospital Universitario Fundacion Jimenez Diaz
  • Valencia, Spain, 46026
    • Hospital Universitari i Politecnic La Fe
  • Avenida De Córdoba Sin Número
    • Madrid, Avenida De Córdoba Sin Número, Spain, 28041
      • Hospital Universitario 12 de Octubre
  • Badalona
    • Barcelona, Badalona, Spain, 08916
      • Hospital Germans Trias i Pujol
  • Calle De Arturo Soria
    • Madrid, Calle De Arturo Soria, Spain, 270
      • MD Anderson Cancer Center Madrid
• United States
  • California
    • Los Angeles, California, United States, 990095
      • University of California Los Angeles (UCLA)
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • The Blood and Marrow Transplant Group of Georgia
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago Medical Center
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health and Science University
  • Texas
    • Dallas, Texas, United States, 75246
      • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    • Houston, Texas, United States, 77030
      • University of Texas MD Anderson Cancer Center
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Froedtert Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adults ≥18 years of age with acute myeloid leukemia (AML) and at least 1 prior line of therapy
• FMS-like tyrosine kinase 3 (FLT3)-mutated disease documented in a local reference laboratory at the time of consideration for enrollment in the study
• Have the ability to understand the requirements and procedures of the study and sign a written informed consent form
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2
• Adequate hepatic and renal function
• Prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR) ≤1.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
• Negative serum ß-human chorionic gonadotropin (HCG) test in women of child-bearing potential (WOCBP)
• Left ventricular ejection fraction ≥50% confirmed by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan

Exclusion Criteria:

• Known central nervous system (CNS) involvement with leukemia
• Clinical signs/symptoms of leukostasis that have failed therapy including hydroxyurea and/or leukapheresis of at least 3 days duration
• Pregnant or breastfeeding women
• Active infection with hepatitis B, C or human immunodeficiency virus (HIV) infection
• Disseminated intravascular coagulation with active bleeding or signs of thrombosis
• Known active coronavirus disease 2019 (COVID-19)
• Administration of a live attenuated virus vaccine within 35 days before Cycle 1 Day 1 (C1D1)
• History of non-myeloid malignancy except for the following: adequately treated localized basal cell, or squamous cell carcinoma of the skin, or localized melanoma (with TNM stage either Tis [melanoma in-situ] or T1aN0M0) with complete resection; cervical carcinoma in situ; superficial bladder cancer; asymptomatic prostate cancer without known metastatic disease, with no requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for > 1 year prior to start of study therapy; or any other cancer that has been in complete remission without treatment for ≥3 years prior to enrollment
• Clinically significant heart disease
• Prolongation of the long measure between Q wave and T wave in the electrocardiogram (QT) interval at baseline
• Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection at the time of study treatment initiation
• Current (within 30 days of study enrollment) drug-induced liver injury, chronic active hepatitis, alcoholic liver disease, nonalcoholic steatohepatitis, primary biliary cholangitis with inadequate response to ursodeoxycholic acid or other health authority approved therapy, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, or portal hypertension
• Ongoing (within 6 weeks of study enrollment) hepatic encephalopathy
• Ongoing immunosuppressive therapy, including systemic chemotherapy for treatment of leukemia

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LANRA 20 mg QD + Gilteritinib 120 mg QD; Participants received LANRA 20 mg once daily (QD) as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a partial remission (PR) after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.	Drug: Lanraplenib; Orally via tablets; Other Names: LANRA; Drug: Gilteritinib; Orally via tablets; Other Names: XOSPATA®
Experimental: LANRA 40 mg QD + Gilteritinib 120 mg QD; Participants received LANRA 40 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a PR after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.	Drug: Lanraplenib; Orally via tablets; Other Names: LANRA; Drug: Gilteritinib; Orally via tablets; Other Names: XOSPATA®
Experimental: LANRA 60 mg QD + Gilteritinib 120 mg QD; Participants received LANRA 60 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a PR after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.	Drug: Lanraplenib; Orally via tablets; Other Names: LANRA; Drug: Gilteritinib; Orally via tablets; Other Names: XOSPATA®
Experimental: LANRA 90 mg QD + Gilteritinib 120 mg QD; Participants received LANRA 90 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 1. Participants also received gilteritinib 120 mg QD as oral tablets in consecutive 28-day cycles starting from Cycle 1 Day 2. Participants received treatment until progression/relapse or lack of at least a PR after 6 months of study treatment, intolerance, or withdrawal from treatment by the participant or study investigator.	Drug: Lanraplenib; Orally via tablets; Other Names: LANRA; Drug: Gilteritinib; Orally via tablets; Other Names: XOSPATA®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)	A TEAE was any unfavorable or unintended sign, symptom, laboratory abnormality or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered causally related to the study drug or not that started after the first dose of the earliest study drug through the lesser of non-protocol anti-leukemic therapy initiation or end of treatment visit. A serious TEAE was defined as any TEAE that: Resulted in death.; Was life-threatening.; Required or prolonged a pre-existing hospitalization.; Resulted in disability/incapacity.; Was a congenital anomaly/birth defect.; Was considered a significant medical event by the investigator. TEAEs were graded for severity based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 as follows: Grade 1 - Mild.; Grade 2 - Moderate.; Grade 3 - Severe.; Grade 4 - Life-threatening.; Grade 5 - Death related to adverse event (AE).	Cycle 1 Day 1 (each cycle was 28 days) to 30 days after last dose of either LANRA or gilteritinib or initiation of non-protocol antileukemic therapy, whichever was earlier (maximum duration of treatment was 183 days)
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) for LANRA	A DLT was defined as any of the following occurring within the DLT assessment period: A nonhematologic toxicity of Grade ≥ 3 that was at least possibly related to LANRA (with noted exceptions).; Any toxicity that resulted in administration of < 80% of the cumulative, Cycle 1 dose for either LANRA or gilteritinib.; Grade 4 neutropenia or thrombocytopenia lasting > 28 days after treatment onset that was not attributed to active acute myeloid leukemia (AML) and was at least possibly related to LANRA.; Any toxicity that resulted in reduction in the dose of LANRA in Cycle 1. DLTs were graded for severity based on the NCI-CTCAE version 5.0 as follows: Grade 3 - Severe.; Grade 4 - Life-threatening.	Cycle 1 Day 1 to pre-dose Cycle 2 Day 1 (each cycle was 28 days)
Maximally Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of LANRA in Combination With Standard Doses of Gilteritinib	The MTD/RP2D was defined as the highest dose with either 0 of 3 or no more than 1 of 6 patients with LANRA-related DLTs. All decisions regarding dose escalation including declaration of the MTD/RP2D were made by the dose-escalation committee (DEC).	Cycle 1 Day 1 to pre-dose Cycle 2 Day 1 (each cycle was 28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximal Plasma Concentration (Cmax) of LANRA	Cmax was derived from plasma concentrations of LANRA using standard non-compartmental methods and actual sample times.	Cycle 1 Day 1 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose.
Time to Cmax (Tmax) of LANRA	Tmax was derived from plasma concentrations of LANRA using standard non-compartmental methods and actual sample times.	Cycle 1 Day 1 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose.
Area of the Plasma Concentration x Time Curve From Hour 0 to the Last Measurable Time Point (AUC0-last) of LANRA	AUC0-last was derived from plasma concentrations of LANRA using standard non-compartmental methods and actual sample times.	Cycle 1 Day 1 and Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose.
Cmax of Gilteritinib	Cmax was derived from plasma concentrations of gilteritinib using standard non-compartmental methods and actual sample times.	Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose.
Tmax of Gilteritinib	Tmax was derived from plasma concentrations of gilteritinib using standard non-compartmental methods and actual sample times.	Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose.
AUC0-last of Gilteritinib	AUC0-last was derived from plasma concentrations of gilteritinib using standard non-compartmental methods and actual sample times.	Cycle 1 Day 15: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 hours post-dose.
Composite Complete Remission (cCR) Rate Per European LeukemiaNet (ELN) 2017 Criteria	Percentage of participants with cCR included CR and CR with partial hematologic recovery (CRh). CR required all of the following, per ELN 2017 criteria: Bone marrow blasts < 5 %.; Absence of circulating blasts and blasts with Auer rods.; Absence of extramedullary disease (ie, leukemia outside of bone marrow confirmed by biopsy).; Absolute neutrophil count > 1.0 x 10^9/L (1,000/μL).; Platelet count >100 x 10^9/L (100,000/μL). CRh required all aforementioned CR criteria except for the below: Absolute neutrophil count > 0.5 x 10^9/L (500/μL) and/or;; Platelet count > 50 x 10^9/L (50,000/μL).	Cycle 1 Day 1 until occurrence of documented CR or CRh (maximum duration of follow-up was 16.1 months).
Duration of Response (DOR)	DOR was defined as the time from first qualifying response (CR/CRh) until relapse or death from any cause, as assessed by study investigators. CR required all of the following: Bone marrow blasts < 5 %.; Absence of circulating blasts and blasts with Auer rods.; Absence of extramedullary disease (ie, leukemia outside of bone marrow confirmed by biopsy).; Absolute neutrophil count > 1.0 x 10^9/L (1,000/μL).; Platelet count >100 x 10^9/L (100,000/μL). CRh required all aforementioned CR criteria except for the below: Absolute neutrophil count > 0.5 x 10^9/L (500/μL) and/or;; Platelet count > 50 x 10^9/L (50,000/μL). Relapse was defined as the reappearance of circulating blasts or ≥ 5% blasts in the bone marrow not attributable to any other cause or reappearance of cytologically or biopsy documented extramedullary disease.	From first qualifying response (CR/CRh) until relapse or death from any cause (maximum duration of follow-up was 16.1 months).
Event-free Survival (EFS)	EFS was defined as the time from treatment onset until treatment failure (ie, failure to achieve CR/CRh, relapse from CR/CRh, or death from any cause). CR required all of the following: Bone marrow blasts < 5 %.; Absence of circulating blasts and blasts with Auer rods.; Absence of extramedullary disease (ie, leukemia outside of bone marrow confirmed by biopsy).; Absolute neutrophil count > 1.0 x 10^9/L (1,000/μL).; Platelet count >100 x 10^9/L (100,000/μL). CRh required all aforementioned CR criteria except for the below: Absolute neutrophil count > 0.5 x 10^9/L (500/μL) and/or;; Platelet count > 50 x 10^9/L (50,000/μL). Relapse was defined as the reappearance of circulating blasts or ≥ 5% blasts in the bone marrow not attributable to any other cause or reappearance of cytologically or biopsy documented extramedullary disease.	Cycle 1 Day 1 to treatment failure (ie, failure to achieve CR or CRh, relapse from CR/CRh or death from any cause) (maximum duration of follow-up was 16.1 months).
Overall Survival	Overall survival was defined as the time from enrollment until death from any cause. Overall survival was estimated using Kaplan-Meier methodology.	Enrollment until death from any cause (maximum duration of follow-up was 16.1 months).

Collaborators and Investigators

• Sponsor: Kronos Bio

Study record dates

Study Major Dates

• Study Start (Actual): August 5, 2022
• Primary Completion (Actual): April 9, 2024
• Study Completion (Actual): April 9, 2024

Study Registration Dates

• First Submitted: August 25, 2021
• First Submitted That Met QC Criteria: August 25, 2021
• First Posted (Actual): August 31, 2021

Study Record Updates

• Last Update Posted (Actual): August 7, 2024
• Last Update Submitted That Met QC Criteria: July 11, 2024
• Last Verified: July 1, 2024

More Information

Terms related to this study

• Keywords: Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Lanraplenib; LANRA
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; Gilteritinib
• Other Study ID Numbers: KB-LANRA- 1001; 2022-001279-15 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No